A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis (ADmIRe)

I9N-MC-FCAB -

The reason for this study is to see if the study drug LY3375880 is safe and effective in adults with moderate-to-severe atopic dermatitis (AD).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
What the trial is testing?
Could I receive a Placebo?
Yes
Enrollment Goal
136
Trial Dates
Feb 12, 2019 - Feb 27, 2020
How long will I be in the trial?
The study will last about 65 weeks and may include up to 18 visits.
Trial Phase
II

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.